Transfusion in Special Populations (Pregnancy, Neonates, Immunocompromised)

Some patient groups require transfusion considerations that differ from those for the general adult. Neonates and especially preterm infants have distinct physiology and their own threshold trials; pregnant patients raise concerns about alloimmunisation and the fetus; and immunocompromised recipients need component modifications to prevent specific complications. This topic gathers those population-specific principles.

Definition

Transfusion in special populations is the body of population-specific evidence and practice governing how blood components are selected, modified, and given to neonates, pregnant patients, and immunocompromised recipients, whose physiology or vulnerability differs from that of general adult patients.

Scope

The entry covers transfusion thresholds in preterm and term neonates, considerations in pregnancy including red-cell alloimmunisation and obstetric haemorrhage, and the component modifications — such as irradiation to prevent transfusion-associated graft-versus-host disease and measures to reduce cytomegalovirus risk — used for vulnerable recipients. It is a reference overview, not individualised clinical guidance.

Core questions

• How do transfusion thresholds for preterm and term neonates differ from those for adults?
• What transfusion considerations are specific to pregnancy?
• Why and for whom are blood components irradiated?
• How is cytomegalovirus risk addressed in vulnerable recipients?

Key concepts

• Neonatal transfusion thresholds
• Red-cell alloimmunisation in pregnancy
• Transfusion-associated graft-versus-host disease
• Irradiated blood components
• CMV-reduced-risk components
• Small-volume (aliquot) transfusion

Mechanisms

Neonatal transfusion practice is informed by trials specific to this population: the PlaNeT-2 trial found that a higher platelet-count threshold for prophylactic transfusion in preterm neonates was associated with worse outcomes than a lower threshold, cautioning against liberal platelet use (curley-2019), and the TOP trial found no benefit from a higher haemoglobin threshold for red-cell transfusion in extremely-low-birth-weight infants (kirpalani-2020). In pregnancy, exposure to non-self red-cell antigens can provoke alloantibodies that threaten the current or a future fetus, so antigen-matching and antibody surveillance are central. Immunocompromised recipients are at risk of transfusion-associated graft-versus-host disease from donor lymphocytes, prevented by irradiating cellular components, and of cytomegalovirus transmission, mitigated by leukoreduction or seronegative components (vamvakas-2009). Platelet transfusion thresholds in these and other settings are addressed in synthesising guidelines (kaufman-2015).

Clinical relevance

Recognising that thresholds and component requirements differ for neonates, pregnant patients, and immunocompromised recipients underlies safe transfusion across the lifespan. This entry summarises the relevant evidence and concepts; it does not provide thresholds, doses, or product selection for any individual patient, which require specialist assessment and current protocols.

Evidence & guidelines

Population-specific randomised trials (PlaNeT-2 in neonatal platelets, TOP in preterm red cells) and platelet-transfusion guidelines from the AABB inform practice in these groups, alongside haemovigilance evidence on preventable transfusion harms (curley-2019, kirpalani-2020, kaufman-2015, vamvakas-2009).

History

Neonatal and obstetric transfusion long relied on extrapolation from adult practice, but dedicated trials in the 2010s and 2020s began to provide population-specific evidence, while the recognition of transfusion-associated graft-versus-host disease and cytomegalovirus transmission established the modern use of irradiation and leukoreduction for at-risk recipients (curley-2019, kirpalani-2020, vamvakas-2009).

Debates

Should neonates be transfused at higher thresholds for presumed safety?

Intuition once favoured liberal transfusion in fragile newborns, but the PlaNeT-2 and TOP trials found that higher platelet and haemoglobin thresholds did not improve, and in the case of platelets worsened, outcomes, supporting more restrictive neonatal practice.

Seminal works

• curley-2019
• kirpalani-2020
• kaufman-2015

Frequently asked questions

Why are blood components irradiated for some patients?

Irradiation inactivates donor lymphocytes that could otherwise cause transfusion-associated graft-versus-host disease, a rare but often fatal complication, in severely immunocompromised and certain other at-risk recipients.

Do preterm infants need transfusion at higher thresholds than adults?

Dedicated trials such as PlaNeT-2 and TOP found that higher platelet and haemoglobin thresholds did not benefit preterm infants and could be harmful, so neonatal practice has moved toward more restrictive thresholds rather than higher ones.